Abstract
Oxalate nephropathy is a rare condition but remains an important cause of end-stage kidney disease. A 42-year-old healthy man with no comorbid was sent to a nephrologist because of significantly increased creatinine (290-836 µmol/l) within 3 months. He was found to have renal impairment when he was treated for pneumonia a few months earlier. The initial workup was unrevealing. Within a couple of weeks after the first visit, he developed acute symptomatic worsening kidney injury with nausea, vomiting and creatinine up to 836 µmol/l. Further history revealed that he had sought alternative treatment with multiple supplements containing high doses of vitamin C and foods high in oxalate precursor. A kidney biopsy confirmed oxalate nephropathy. Despite restriction of oxalate consumption, his kidney function deteriorated and he commenced on permanent hemodialysis.
References
Bhasin B., Urekli H.M., Atta M.G. Primary and secondary hyperoxaluria: understanding the enigma. World J Nephrol. 2015;4:235–244.
Milliner DS. The primary hyperoxalurias: an algorithm for diagnosis. Am J Nephrol. 2005;25:154–160.
Hellman L, Burns JJ. Metabolism of L-ascorbic acid-1-C14 in man. J Biol Chem. 1958;230:923–930.
Lamarche J , Nair R , Peguero A , et al. Vitamin C-induced oxalate nephropathy. Int J Nephrol 2011; 2011: 1-4
Chen CL, Fang HC, Chou KJ, Wang JS, Chung HM. Acute oxalate nephropathy after ingestion of star fruit. American Journal of Kidney Diseases. 2001;37(2):418–422.
Sasaki M, Murakami M, Matsuo K, et al. Oxalate nephropathy with a granulomatous lesion due to excessive intake of peanuts. Clinical and Experimental Nephrology. 2008;12(4):305–308.
Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clinical Nephrology. 2009;71(4):430–432.
Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. American Journal of Kidney Diseases. 2007;49(1):153–157.
Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases. 2005;1(5):481–485.
Atkins GL, Dean BM, Griffin WJ, Watts RWE. Quantitative aspects of ascorbic acid metabolism in man. J Biol Chem. 1964;239:2975–2980.
Baker EM, Saari JC, Tolbert BM. Ascorbic acid metabolism in man. Amer J Clin Nutr. 1966;19:371–378.
Pietro manuel Ferraro,MD, Gary C.Curhan,MD. Total,dietary and supplemental Vitamin C intake and risk of incident kidney stones. AM J Kidney Dis.2016 Mar; 67(3): 400-407
Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Australian and New Zealand Journal of Medicine. 1994;24(4):410–411.
Sullivan JF, Eisenstein AB. Ascorbic acid depletion in patients undergoing chronic hemodialysis. American Journal of Clinical Nutrition. 1970;23(10):1339–1346.
Sullivan JF, Eisenstein AB. Ascorbic acid depletion during hemodialysis. Journal of the American Medical Association. 1972;220(13):1697–1699.
Lawton JM, Conway LT, Crosson JT. Acute oxalate nephropathy after massive ascorbic acid administration. Archives of Internal Medicine. 1985;145(5):950–951.
Ono K. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients. Clinical Nephrology. 1986;26(5):239–243.
24. Nasr SH, Kashtanova Y, Levchuk V, Markowitz GS. Secondary oxalosis due to excess vitamin C intake. Kidney International. 2006;70(10):p. 1672.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Journal of Clinical and Translational Nephrology